-

Thermo Fisher Scientific’s Clinical Research Business Receives ATD Award for Employee Talent Development

WILMINGTON, N.C.--(BUSINESS WIRE)--The PPD clinical research business of Thermo Fisher Scientific has been recognized as one of the best in the world for its successful enterprise learning and development programs by the Association for Talent Development (ATD), a global organization that empowers professionals to develop talent in the workplace.

The PPD clinical research business is a recipient of the 2022 ATD BEST Awards, which recognize enterprise-wide success in employee talent development. As a result of effective efforts to attract, develop and retain top talent in the industry, the business was recognized among 72 winners in the 2022 BEST Awards Winners' Circle, which includes small and large private, public and not-for-profit organizations from around the world.

“Our business continues to shape career development for our employees by identifying areas to enhance their knowledge and skills to better serve our customers and to enable colleagues to grow their careers,” said Jay Dixon, senior vice president, quality and enterprise learning, clinical research, Thermo Fisher Scientific. “Through our strategic development programs, we are enhancing our learning culture and providing our colleagues with unique opportunities for growth and success while helping to retain top talent within the industry.”

The ATD BEST Awards celebrate and honor those companies that use talent development as a strategic business tool to deliver results. Employee learning and development at the PPD clinical research business includes leadership and high-potential development, key talent programs, technical skills, and job-specific and soft skills training. One of the key offerings is the Core Professional Skills Program, also referred to as Core Pro, which helps employees develop necessary business skills and increase individual effectiveness in order to provide exceptional customer service.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

Contacts

Media:
Nadine Maeser
Clinical Research, Thermo Fisher Scientific
(910) 558-4779
nadine.maeser@ppd.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Summary
The PPD clinical research business of Thermo Fisher Scientific has been recognized for its successful enterprise learning and development programs.
Release Versions

Contacts

Media:
Nadine Maeser
Clinical Research, Thermo Fisher Scientific
(910) 558-4779
nadine.maeser@ppd.com

More News From Thermo Fisher

Nalgene Outdoor Introduces Fresh Flow™ Straw Bottle

ROCHESTER, N.Y.--(BUSINESS WIRE)--Nalgene Outdoor today introduces the Fresh Flow™ straw bottle, a new addition to its reusable bottle collection designed to give fans more ways to hydrate without sacrificing the simplicity, durability, and approachable price points they expect from a Nalgene bottle. The result is a slim 24-oz bottle paired with a new interchangeable Fresh Flow cap that lets fans sip from a straw, chug from a spout, or swap the cap onto other Nalgene bottles they already own. T...

Thermo Fisher Scientific’s Clinical Research Business Named a Leader Among CROs in 2026 ISG Provider Lens™ Report for Use of AI in Clinical Trials

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, earned a Leader designation among contract research organizations (CROs) in the 2026 ISG Provider Lens™ Life Sciences Digital Services report, underscoring the company’s continued investment in digital innovation across the clinical development continuum. The recognition highlights the strength of Thermo Fisher’s PPD™ clinical research business, which is recognized for its capabilities in clinic...

Thermo Fisher Scientific Unveils an Integrated Platform to Advance Scalable Cell Therapy Manufacturing

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Gibco™ CTS™ DynaXS™ Single Use Bioreactor, a purpose-built expansion platform designed to help cell therapy developers scale manufacturing with precise control, flexibility, and regulatory readiness. As cell therapies move from early research into clinical development and commercialization, manufacturers face increasing pressure to transition from static culture systems to s...
Back to Newsroom